OnKure Therapeutics, Inc.OKUREarnings & Financial Report
OnKure Therapeutics, Inc. is a clinical-stage biotechnology company specializing in precision oncology therapy development. It focuses on creating targeted small molecule drugs including epigenetic and kinase inhibitors, to address unmet medical needs for patients with hard-to-treat solid tumors and hematologic cancers, serving global oncology patient segments.
OKUR Q3 FY2025 Key Financial Metrics
Revenue
$802.0K
Gross Profit
N/A
Operating Profit
$-15.5M
Net Profit
$-14.7M
Gross Margin
N/A
Operating Margin
-1932.8%
Net Margin
-1832.8%
YoY Growth
1922.7%
EPS
$-1.09
OnKure Therapeutics, Inc. Q3 FY2025 Financial Summary
OnKure Therapeutics, Inc. reported revenue of $802.0K (up 1922.7% YoY) for Q3 FY2025, with a net profit of $-14.7M (down 27.2% YoY) (-1832.8% margin).
Key Financial Metrics
| Total Revenue | $802.0K |
|---|---|
| Net Profit | $-14.7M |
| Gross Margin | N/A |
| Operating Margin | -1932.8% |
| Report Period | Q3 FY2025 |
OnKure Therapeutics, Inc. Quarterly Revenue & Net Profit History
OnKure Therapeutics, Inc. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $802.0K | +1922.7% | $-14.7M | -1832.8% |
| Q2 FY2025 | $934.0K | +357.8% | $-15.4M | -1647.8% |
| Q3 FY2024 | $-44.0K | — | $-11.6M | 26263.6% |
Income Statement
| Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Revenue | $-44000 | $934000 | $802000 |
| YoY Growth | N/A | 357.8% | 1922.7% |
Balance Sheet
| Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Assets | $77.6M | $86.1M | $72.8M |
| Liabilities | $3.6M | $7.9M | $6.4M |
| Equity | $-135.1M | $78.2M | $66.4M |
Cash Flow
| Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Operating CF | $-10.7M | $-13.3M | $-13.0M |